||EPS - Basic
||Market Cap (m)
BTG Share Discussion Threads
Showing 4451 to 4468 of 4475 messages
|Indeed,suggests to my mind that they're going to issue another self congratulatory update that has little cognisance to the likely disappointment of the market .Expectations are being badly managed by the company which has the audacity to applaud itself for not paying a dividend!|
|bounced off downtrend resistance and looks to be continuing the downtrend sold!
|Two weeks to go to the closed period update...two weeks of trader pessimism.Then fgs, let's hope for a glowing report across the group and NO nasty surprises!Dum spiro.....|
|From eye eye eye
Anti-Venom Market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12%.
Press release from: Market Data Forecast
According to the report Global Anti-Venom Market, published by Market Data Forecast, the global market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12% from 2016 to 2021.
For full report refer to
Anti-venom is the organic product that detoxifies poisoning of fatal bites and stings. It is prepared from the milking venom of toxic animals such as snakes, spiders, scorpions, and other poisonous animals. Anti-venom is also known as “venom antiserum” and “anti-venom immunoglobulin. It is evaluated that, approximately 100,000 people die worldwide with snake bites annually. To vanquish poisonous effects after venomous bites, Anti-venom products are emerged including vaccines and hyper immune sera.
Free sample for the report is available at
The prime factors that are compelling the expansion of the market are increase in the government initiations to promote the progress of high quality anti-venom products, existence of highest number of snake bite victims and appraise pipeline products launch. Additionally, advancement of deaths from venomous animal’s bites and inclining research to merge advanced anti-venom products is further stimulating the growth of Anti-venom Market. The key restraints of Anti-venom market are withdrawal of anti-venom products, insufficient funding to enlarge the anti-venom products to meet demand, high cost of the products, regulatory entanglements, and high costs of maintaining livestock for anti-venom.
Avail discount at
By Hyperimmune sera
• North America Anti-venom Market
• Europe Anti-venom Market
• Asia-Pacific Anti-venom Market
• Latin America Anti-venom Market
• Middle-East & Africa Anti-venom Market
Enquire more about the report at
The key competitors in the Anti-Venom market are Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bio products Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh), and Bharat Serum and Vaccines Limited (BSV) (India).
FIO CIAO Paulo|
|Sell off today was done by selling programm . Who was behind this programm shortsellers or just sellers I dont know.
Broker told that trades were automated by robot.
Dame Louis doesn't want protect her shareholders imo|
|Mark my words, because I know about these things (touching side of nose), it is Varithena, and only Varithena, that is causing markets all over the world to drop steeply. Trump's inability to get his health insurance changes through is merely the fart on the edge of the thunderstorm.
|I'd be very surprised if Varithena was to surprise for the better if the recent price movement is anything to go by.|
|Presumably the shorters will push the share price down for the next two weeks anticipating poor news on Varithena?|
|This chart sucks!
Hopefully next weeks results can lead to a breakout,as has happened to Ventura this morning.|
|Does Louise know how boring it is on this thread.|
|oh what a lovely bunch of coconuts|
|Oh what a lovely war ?|
|Cannot wait , hope the trading update is a Oh My and not a Oh God.|
|oh (sing along if you know the words)|
|Trading update due Thursday,6 April.Final results due Tuesday 16th May.|
|Sorry - the name's Bond.|
|Thanks , was just thinking to myself must have missed Wellbutrin.
Sorry for sounding negative in the above , but wishing to see a good set of results before we should be announcing a screaming buy at these levels.|
|Sorry that should have been Vistogard, not Wellbutrin!|